MedPacto Financials
| 235980 Stock | KRW 4,425 135.00 2.96% |
MedPacto |
Understanding current and past MedPacto Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of MedPacto's financial statements are interrelated, with each one affecting the others. For example, an increase in MedPacto's assets may result in an increase in income on the income statement.
Please note, the presentation of MedPacto's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, MedPacto's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of MedPacto's management manipulating its earnings.
MedPacto Stock Summary
MedPacto competes with ABL Bio, ALTEOGEN, Kmw, and Celltrion Pharm. MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers MS-1601A that targets TRG1 for cancers and autoimmune diseases and vactosertib for solid tumors. MedPacto is traded on Korean Securities Dealers Automated Quotations in South Korea.| Instrument | Korea Stock View All |
| Exchange | KOSDAQ |
| Business Address | Borim Building, Seoul, |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.medpacto.com |
| Phone | 82 2 6938 0200 |
| Currency | KRW - South Korean Won |
You should never invest in MedPacto without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of MedPacto Stock, because this is throwing your money away. Analyzing the key information contained in MedPacto's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
MedPacto Key Financial Ratios
MedPacto's financial ratios allow both analysts and investors to convert raw data from MedPacto's financial statements into concise, actionable information that can be used to evaluate the performance of MedPacto over time and compare it to other companies across industries.| Return On Equity | -58.54 | |||
| Return On Asset | -0.25 | |||
| Target Price | 26000.0 | |||
| Z Score | 3.0 |
MedPacto Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining MedPacto's current stock value. Our valuation model uses many indicators to compare MedPacto value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MedPacto competition to find correlations between indicators driving MedPacto's intrinsic value. More Info.MedPacto is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value MedPacto by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for MedPacto's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.MedPacto Systematic Risk
MedPacto's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. MedPacto volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on MedPacto correlated with the market. If Beta is less than 0 MedPacto generally moves in the opposite direction as compared to the market. If MedPacto Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one MedPacto is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of MedPacto is generally in the same direction as the market. If Beta > 1 MedPacto moves generally in the same direction as, but more than the movement of the benchmark.
MedPacto December 21, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of MedPacto help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of MedPacto. We use our internally-developed statistical techniques to arrive at the intrinsic value of MedPacto based on widely used predictive technical indicators. In general, we focus on analyzing MedPacto Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build MedPacto's daily price indicators and compare them against related drivers.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 23.66 | |||
| Value At Risk | (4.91) | |||
| Potential Upside | 5.22 |
Complementary Tools for MedPacto Stock analysis
When running MedPacto's price analysis, check to measure MedPacto's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MedPacto is operating at the current time. Most of MedPacto's value examination focuses on studying past and present price action to predict the probability of MedPacto's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MedPacto's price. Additionally, you may evaluate how the addition of MedPacto to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stocks Directory Find actively traded stocks across global markets |